Lineage, Inc. is a biotech company focused on advancing regenerative medicine and developing therapeutic solutions for patients with degenerative diseases and injuries
The company utilizes innovative technologies, including stem cell research and tissue engineering, to create treatments aimed at restoring function and improving quality of life. Through its research and development efforts, Lineage seeks to bring groundbreaking therapies to market, addressing unmet medical needs in various fields such as ophthalmology, neurology, and orthopedics. By leveraging scientific advancements and collaborative partnerships, Lineage continues to work towards its mission of transforming medicine and enhancing patient outcomes.
Lineage shares rise after multiple firms initiate coverage with Buy ratings. JPMorgan analyst initiates with Overweight rating and $93 price target, citing challenges in cold storage business but expects improved trends. Lineage heavily invests in technology and acquisitions, with potential for above-forecasted growth. BofA Securities analyst maintains Buy rating and $100 price target, highlighting competitive advantage and investments in technology. Truist Securities analyst starts coverage with Buy rating and $94 price target, anticipating rebound in food sector and strong market position for Lineage.
Lineage jumped as much as 5% in their debut on the Nasdaq earlier this week. The largest temperature-controlled warehouse real estate investment trust in the world raised $4.4B at an implied valuation of $18B, making it the largest IPO since Arm.
